Press Releases Legend Biotech Corporation

Equities

LEGN

US52490G1022

Real-time Estimate Cboe BZX Other stock markets 19:05:42 13/09/2024 BST			5-day change	1st Jan Change
50.66 ^USD	-0.13%		+5.05%	-15.69%

09-04	Transcript : Legend Biotech Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 02:35 PM
08-27	Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients	08-28	AQ
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	08-20	GL
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights	08-12	AQ
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights	08-09	GL
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights	08-09	AQ
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors	08-08	GL
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024	07-26	GL
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended June 30, 2024 Form 6 K	07-17	PU
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results	07-10	GL
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma	07-02	GL
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma	07-02	AQ
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA	06-03	BU
Legend Biotech to Participate in the Jefferies Global Healthcare Conference	05-29	BU
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA	05-23	BU
Legend Biotech : LEGN Q1 2024 Earnings Presentation	05-13	PU
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights	05-13	BU
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	04-22	BU
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K	04-16	PU
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results	04-11	BU
Innovative personalised immunotherapy approved for multiple myeloma	04-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Legend Biotech Corporation

Equities

LEGN

US52490G1022

Press Releases

Filters